Data sources

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Open research · Psilocybin & psilocin

Trial pipeline

Track psilocybin trial phases, recruitment, sponsors and registry completion dates with country filters, source links, comparison and free data exports.

Free access · No subscription for research tools or data exports

Filter the development pipeline

Reset

24 trials match this view; 24 reported facilities; 24 have usable coordinates. Latest indexed registry check Nov 19, 2026 02:23 UTC. Country membership uses reported locations, including locations without coordinates; Mapped-facility counts cover all sites of matching trials, including international sites, and require valid coordinates.

Enrollment sum: 1,352 across 24 records with a reported count. Planned and actual counts are mixed; this is not a count of unique treated participants.

Recorded study-start years

20181
20213
20221
20233
20246
20253
20266
20271

Current indexed registry status

Recruiting11
Completed6
Not yet recruiting2
Active, not recruiting2
Unknown status2
Withdrawn1

Reported research conditions

Counts describe indexed registry records, not efficacy or total research activity. A trial can count under several conditions or countries. Unknown dates are excluded from the start-year chart; future years reflect planned starts. Stopped studies may reflect recruitment, funding or strategy and are not automatically treatment failures.

Milestones to investigate

The table is ordered by reported primary completion date. Check whether the registry calls enrollment estimated or actual, when the record was last updated, and whether results have been published. Completion dates are not readout dates; no model-generated success probabilities are assigned.

For late-stage studies, choose PHASE3 above. For studies still underway, choose an exact recruitment status. Use sponsor and country filters to inspect a programme, then save records to compare their designs.

Matching trial records

24 matching registry records. Dates are registry milestones, not promised results announcements.
TrialSponsor and phaseStatusEnrollmentStart / primary completion / completionResearch workflow
Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors

NCT02950467

Distress · Depression · Grief
Joshua Woolley

PHASE1

Completed

Registry updated 2021-01-07

30

ACTUAL

2018-01-05
2019-12-31
2019-12-31
Evaluating the Effect of Length of Time on Selective Serotonin Reuptake Inhibitors (SSRIs) on the Response to Psilocybin-assisted Therapy in Individuals With Mild-moderate Major Depressive Disorder (MDD)

NCT05594667

Depression · Major Depressive Disorder · Mild Depression · Moderate Depression · Depressive Disorder
Cybin Therapeutics Inc.

PHASE2

Withdrawn

Registry updated 2023-07-06

0

ACTUAL

2023-01-01
2023-03-14
2023-03-14
The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density - A Single Dose Randomized, Double Blind, Placebo- Controlled Phase 2 Positron Emission Tomography Study

NCT04630964

Major Depressive Disorder · Depression
Section for Affective Disorders; Northern Stockholm Psychiatry

PHASE2

Completed

Registry updated 2024-04-19

35

ACTUAL

2021-01-01
2023-04-19
2024-04-18
Evidence-guide report · Yngwe et al. · Stockholm trial · 2026
A Randomized, Placebo-controlled Trial of Psychedelic-assisted Psychotherapy With Single Dose Psilocybin for Frontline Clinicians Experiencing COVID-related Symptoms of Depression and Burnout

NCT05163496

Burnout, Caregiver · Burnout, Professional · COVID-19 · Depression · Post Traumatic Stress Disorder · Moral Injury
University of Washington

PHASE3

Completed

Registry updated 2025-03-18

30

ACTUAL

2022-03-03
2023-12-30
2024-06-30
PAPR: Psilocybin-assisted Psychotherapy + Mindfulness-Based Stress Reduction (MBSR) for Front-line Healthcare Provider COVID-19 Related Burnout

NCT05557643

Depression · Burnout, Professional
University of Utah

PHASE1

Completed

Registry updated 2024-11-12

24

ACTUAL

2023-01-02
2024-09-20
2024-09-20
Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: a Pilot Study

NCT04932434

Parkinson Disease · Depression · Anxiety
Joshua Woolley, MD, PhD

PHASE2

Completed

Registry updated 2026-09-03

12

ACTUAL

2021-08-15
2024-12-31
2024-12-31
Low-Income Group Psilocybin Assisted Therapy for Depression: A Feasibility Study

NCT06372197

Depression
Matthew Hicks

NA

Completed

Registry updated 2025-06-05

20

ACTUAL

2024-08-01
2025-05-14
2025-05-14
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-Assisted Psychotherapy in Treating Severe Depression Among Adults With Post-Traumatic Stress Disorder (PTSD).

NCT06141876

Post-traumatic Stress Disorder · Depression
Apex Labs Ltd.

PHASE2

Unknown status

Registry updated 2023-11-29

160

ESTIMATED

2023-12-15
2025-06-15
2025-06-15
A Multi-centre, Double-blinded, Placebo-controlled, Randomised, Phase II Clinical Trial for Psilocybin-assisted Therapy for Alcohol Use Disorder

NCT06444243

Alcohol Use Disorder · Alcohol Dependence · Depression · Anxiety
University of Sydney

PHASE2

Unknown status

Registry updated 2024-06-10

90

ESTIMATED

2024-09
2025-07
2025-12
Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2)

NCT06341426

Major Depressive Disorder · Depression · Treatment-Resistant Depression · Mood Disorders
University Health Network, Toronto

PHASE2

Active, not recruiting

Registry updated 2026-07-09

92

ESTIMATED

2024-02-05
2026-07-28
2026-12-28
A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and Depression

NCT07336238

Anxiety · Depression · Hematopoietic and Lymphatic System Neoplasm · Metastatic Malignant Solid Neoplasm
University of Washington

PHASE2

Active, not recruiting

Registry updated 2026-10-29

16

ACTUAL

2026-05-19
2026-12-01
2027-05-01
Psilocybin and Affective Function in Chronic Lower Back Pain Depression

NCT06355414

Chronic Low-back Pain · Depression
Johns Hopkins University

PHASE1

Recruiting

Registry updated 2026-09-04

40

ESTIMATED

2024-04-22
2026-12-30
2026-12-30
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors

NCT06801041

Depression · Anxiety · Cancer
M.D. Anderson Cancer Center

PHASE2

Recruiting

Registry updated 2026-11-03

20

ESTIMATED

2025-05-23
2027-03-31
2029-03-31
The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease

NCT06455293

Parkinson Disease · Depression
Joshua Woolley, MD, PhD

PHASE2

Recruiting

Registry updated 2026-08-07

60

ESTIMATED

2024-08-19
2027-06
2028-06
Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's Disease

NCT04123314

Depressive Symptoms · Depression · Alzheimer Disease · Mild Cognitive Impairment
Johns Hopkins University

EARLY_PHASE1

Recruiting

Registry updated 2026-09-04

20

ESTIMATED

2021-03-24
2027-06-30
2027-09-30
Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study)

NCT05883540

Palliative Care · Pain · Anxiety · Depression · Demoralization · Psychological Distress · Quality of Life · Caregiver Burden · Fear of Death · Existential Distress
University Hospital, Basel, Switzerland

PHASE2

Recruiting

Registry updated 2026-04-29

60

ESTIMATED

2024-06-09
2027-09
2028-05
A Phase 2 Sequential Dose-Finding Study of Preparation for Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression

NCT07565909

Depression · Anxiety
University of Washington

PHASE2

Not yet recruiting

Registry updated 2026-05-04

72

ESTIMATED

2026-06
2027-12
2028-07
A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe Anxiety

NCT06820723

Depression · Anxiety · Major Depressive Disorder
Ohio State University

PHASE2

Recruiting

Registry updated 2026-10-20

40

ESTIMATED

2026-11-01
2028-11
2028-11
Registry-linked result · PMID 27210031
Registry-linked result · PMID 33146667
Registry-linked result · PMID 36322843
Registry-linked result · PMID 31060042
Registry-linked result · PMID 31636488
Registry-linked result · PMID 37651119
Registry-linked result · PMID 27909164
Registry-linked result · PMID 20717121
An Investigation of Strategies to Understand and Optimize the Antidepressant Effects of Psilocybin (The OPTIMIZE Study)

NCT06512194

Depression
Charles Raison

PHASE2

Recruiting

Registry updated 2026-08-10

141

ESTIMATED

2025-05-13
2029-05
2029-05
Processing Intergenerational Trauma With Psilocybin-Assisted Therapy

NCT06899165

Psychological Stress · Depression · Anxiety
Rachel Yehuda

PHASE2

Recruiting

Registry updated 2026-08-13

100

ESTIMATED

2026-08-28
2029-05-31
2030-01-02
Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive Disorder

NCT06132178

Treatment Resistant Depression · MDD · Major Depressive Disorder · Recurrent Depression · Depression
University of Texas at Austin

PHASE2

Recruiting

Registry updated 2025-11-26

100

ESTIMATED

2025-01-10
2029-12-31
2030-12-31
The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease

NCT07610369

Depression · Parkinson's Disease (PD)
Yale University

PHASE2

Recruiting

Registry updated 2026-09-28

40

ESTIMATED

2026-07-10
2030-07
2030-07
Psilocybin FCR Early-Stage Breast Cancer

NCT07909408

Early-stage Breast Cancer · Fear of Cancer Recurrence · Anxiety · Depression
NYU Langone Health

PHASE2

Not yet recruiting

Registry updated 2026-11-02

100

ESTIMATED

2027-01-02
2031-01-02
2031-08-31
A Pilot Mechanistic Study of Psilocybin-Assisted Therapy as a Treatment for Depression

NCT07582120

Depression
Washington University School of Medicine

PHASE2

Recruiting

Registry updated 2026-11-17

50

ESTIMATED

2026-11-01
2031-06-15
2031-12-15

Reported research facilities

Centre for Addiction and Mental Health (CAMH)Toronto, Ontario, Canada · Coordinates available
Centre for Neurology Studies x UpstreamAbbotsford British Columbia, British Columbia, Canada · Coordinates available
Toronto Western HospitalToronto, Ontario, Canada · Coordinates available
Northern Stockholm Spychiatry ClinicStockholm, Sweden · Coordinates available
Spital Uster AG, Division of Internal MedicineUster, Switzerland · Coordinates available
University Hospital Basel, Division of Clinical Pharmacology and ToxicologyBasel, Switzerland · Coordinates available
University Hospital Geneva, Palliative medicine departmentCollonge-Bellerive, Switzerland · Coordinates available
University Hospital Zurich, Clinic for Radio-Oncology, Competence Centre Palliative CareZurich, Switzerland · Coordinates available
Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington, United States · Coordinates available
Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600Austin, Texas, United States · Coordinates available
Huntsman Mental Health InstituteSalt Lake City, Utah, United States · Coordinates available
Johns Hopkins Center for Psychedelic and Consciousness ResearchBaltimore, Maryland, United States · Coordinates available
Johns Hopkins University School of MedicineBaltimore, Maryland, United States · Coordinates available
NYU Langone HeathNew York, New York, United States · Coordinates available
National University of Natural MedicinePortland, Oregon, United States · Coordinates available
The Ohio State University Department of PsychiatryColumbus, Ohio, United States · Coordinates available
The Parsons Research Center for Psychedelic HealingNew York, New York, United States · Coordinates available
The University of Texas M. D. Anderson Cancer CenterHouston, Texas, United States · Coordinates available
University of California, San FranciscoSan Francisco, California, United States · Coordinates available
University of Colorado Anschutz Medical Campus (CUAMC)Aurora, Colorado, United States · Coordinates available
University of WashingtonSeattle, Washington, United States · Coordinates available
Vail Health Behavioral HealthEdwards, Colorado, United States · Coordinates available
Washington University School of MedicineSt Louis, Missouri, United States · Coordinates available
Yale UniversityNew Haven, Connecticut, United States · Coordinates available

This directory includes reported facilities with and without coordinates. For a country-filtered view, locations are labeled as selected-country sites or international sites of matching trials. Facilities are registry-reported trial sites, not an independently verified clinic or research-centre directory. Current services and contact details must be checked at the source.